Search This Blog

Friday, November 8, 2019

FibroGen shares halted pending news

Nasdaq has suspended trading in FibroGen (FGEN -9.2%) pending the release of news, in this case, roxadustat safety data at the American Society of Nephrology Kidney Week in Washington, DC.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)